Ligand Pharma (LGND) Tops Q2 EPS by 141c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $303.53 -1.39%
EPS Growth %: -25.6%
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -25.6%
Financial Fact:
Weighted average number of common shares - diluted: 23M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.81, $1.41 better than the analyst estimate of $0.40. Revenue for the quarter came in at $18.42 million versus the consensus estimate of $17 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Coforge Ltd (COFORGE:IN) PT Raised to INR2,460 at UBS
- Phillip Securities Upgrades Indusind Bank Ltd (IIB:IN) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
